uniQure (NASDAQ:QURE) Stock Rating Upgraded by Raymond James

uniQure (NASDAQ:QURE) was upgraded by investment analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has a $52.00 target price on the biotechnology company’s stock, up from their prior target price of $20.00. Raymond James’ target price would indicate a potential upside of 232.27% from the company’s previous close.

Several other research firms have also weighed in on QURE. Cantor Fitzgerald raised their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. Royal Bank of Canada decreased their price target on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Wednesday, November 6th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Thursday, October 17th. Finally, The Goldman Sachs Group cut their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $30.57.

uniQure Price Performance

NASDAQ:QURE opened at $15.65 on Tuesday. uniQure has a 52-week low of $3.73 and a 52-week high of $17.39. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $762.78 million, a P/E ratio of -3.16 and a beta of 0.89. The business’s 50-day moving average price is $6.64 and its 200 day moving average price is $6.22.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, sell-side analysts predict that uniQure will post -3.74 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.74% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of QURE. abrdn plc grew its stake in shares of uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after buying an additional 1,528,581 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of uniQure during the 3rd quarter worth $7,360,000. Point72 Asset Management L.P. increased its stake in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares during the last quarter. FMR LLC raised its holdings in shares of uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in uniQure in the second quarter worth $815,000. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.